Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation

JCO Precis Oncol. 2022 Oct:6:e2200349. doi: 10.1200/PO.22.00349.

Anastasia Navitski¹, Duaa H Al-Rawi², Vicky Makker^{2

3}, Britta Weigelt⁴, Dmitriy Zamarin^{2

3}, Ying Liu^{2

3

5}, Angela G Arnold⁵, M Herman Chui⁴, Diana L Mandelker⁴, Michael Walsh⁵, Deborah F DeLair⁶, Karen A Cadoo⁷, Roisin E O'Cearbhaill^{2

3}

¹ Department of Obstetrics and Gynecology, Augusta University, Augusta, GA.
² Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Medicine, Weill Cornell Medical College, New York, NY.
⁴ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
⁵ Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Department of Pathology, New York University, New York, NY.
⁷ St James's Hospital, Trinity College Dublin, Trinity St James's Cancer Institute, Dublin, Ireland.

No abstract available

Publication types